Stocks Health care MGX
NASDAQ · Health careMetagenomi Therapeutics, Inc. (MGX)
It posted a net loss of $93.5M. In fiscal 2025 capital spending exceeded operating cash flow by $89.5M. At June 30, 2026 it held $39M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Metagenomi Therapeutics, Inc.
- Net worth
- Metagenomi Therapeutics, Inc. has a market value (market cap) of $26.4M at the latest share price, and shareholders' equity of $112.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $25.2M (-51.8% year on year), with a net loss of $87.9M.
- Cash flow
- In fiscal 2025 operations used $88.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Metagenomi Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Metagenomi Therapeutics, Inc. does
Metagenomi Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $25.2M | -$87.9M | -$2.36 | -$89.5M |
| 2024 | $52.3M | -$78.1M | -$2.36 | -$112.2M |
| 2024 | $44.8M | -$68.3M | -$20.05 | -$101.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MGX ranks in Health care
Latest SEC filings
What Metagenomi Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026
- September 10, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026
- August 10, 2026
- June 10, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 70% to $1.2M versus the same quarter last year; diluted EPS -$0.61 versus -$0.68.
- May 11, 2026
- April 27, 2026
- April 27, 2026Additional proxy material DEFA14A
- April 27, 2026Proxy statement DEF 14A
Insider trades
What the people running Metagenomi Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $23.4K and sold $5.1K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 9, 2026 | Reid LaurenceDirector | Bought | 19,883 | $23.3K |
| September 9, 2026 | Reid LaurenceDirector | Bought | 117 | $138.1 |
| September 8, 2026 | Wapnick PamelaChief Financial Officer | Sold | 1,911 | $2.2K |
| September 8, 2026 | Irish JianSee Remarks, Director | Sold | 2,140 | $2.5K |
| September 8, 2026 | Wein MatthewSee Remarks | Sold | 358 | $414.7 |
| June 5, 2026 | Wein MatthewSee Remarks | Sold | 558 | $724.8 |
| June 5, 2026 | Irish JianSee Remarks, Director | Sold | 3,737 | $4.9K |
| June 5, 2026 | Wapnick PamelaChief Financial Officer | Sold | 2,884 | $3.7K |
Who owns MGX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Thomas Brian C.13G, passive | 7.3% | September 10, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 43 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1,077,700 | +19,756 |
| Renaissance Technologies LLC | 742,400 | -45,500 |
| Catalio Capital Management, LP | 528,993 | 0 |
| Peapod Lane Capital LLC | 525,024 | +8,263 |
| Two Sigma Investments, LP | 513,701 | +16,934 |
| Bridgeway Capital Management, LLC | 400,300 | +4,500 |
| Wells Fargo & Company | 379,508 | +177,370 |
| Geode Capital Management, LLC | 288,665 | -69,535 |
| Pura Vida Investments, LLC | 264,391 | 0 |
| BlackRock, Inc. | 257,631 | +27,497 |
| Vanguard Fiduciary Trust Co | 171,251 | +1,077 |
| Jacobs Levy Equity Management, Inc | 160,000 | -222,153 |
| State Street Corp | 119,850 | -577 |
| Millennium Management LLC | 114,025 | -56,079 |
| Man Group plc | 109,130 | +30,494 |
| Resolute Advisors LLC | 89,944 | 0 |
| Marquette Asset Management, LLC | 72,121 | new |
| Northern Trust Corp | 68,938 | -6,234 |
| RBF Capital, LLC | 64,021 | 0 |
| XTX Topco Ltd | 55,707 | +15,125 |
Insiders
5 insiders reported holding 3,239,066 shares in total, about $2.3M at the last price.
| Holder | Shares |
|---|---|
| Thomas Brian C.Director | 2,510,960 |
| Irish JianSee Remarks, Director | 375,393 |
| Wapnick PamelaChief Financial Officer | 206,580 |
| Wein MatthewSee Remarks | 126,133 |
| Reid LaurenceDirector | 20,000 |
Questions about MGX
What does Metagenomi Therapeutics, Inc. do?
Metagenomi Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as MGX. Its shares trade on NASDAQ under the ticker MGX.
What is Metagenomi Therapeutics, Inc.'s net worth?
Metagenomi Therapeutics, Inc. has a market value (market cap) of $26.4M at the latest share price, and shareholders' equity of $112.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Metagenomi Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $93.5M.
When did Metagenomi Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 22, 2026.
When is Metagenomi Therapeutics, Inc.'s next earnings report?
Metagenomi Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MGX with
Follow MGX
Get an email when Metagenomi Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Metagenomi Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.